Dietary Intake of Carotenoids and Their Antioxidant and Anti-Inflammatory Effects in Cardiovascular Care

Marco Matteo Ciccone,^1^ Francesca Cortese,^1^ Michele Gesualdo,^1^ Santa Carbonara,^1^ Annapaola Zito,^1^ Gabriella Ricci,^1^ Francesca De Pascalis,^1^ Pietro Scicchitano,^1^ and Graziano Riccioni^2^  

^1^ Cardiovascular Diseases Section, Department of Emergency and Organ Transplantation (DETO), University of Bari, Piazza G. Cesare 11, 70124 Bari, Italy  
^2^ Intensive Cardiology Care Unit, San Camillo de Lellis Hospital, Via Isonzo 1, 71043 Manfredonia, Italy

Correspondence should be addressed to Graziano Riccioni; griccioni@hotmail.com

Received 14 May 2013; Revised 19 September 2013; Accepted 10 October 2013

Academic Editor: Muzamil Ahmad

Copyright © 2013 Marco Matteo Ciccone et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cardiovascular disease related to atherosclerosis represents nowadays the largest cause of morbidity and mortality in developed countries. Cardiovascular disease related to atherosclerosis represents nowadays the largest cause of morbidity and mortality in developed countries. Despite the reduction of ischemic heart disease rates in the past three decades, recent estimates confirmed its pivotal role in determining the overall mortality until 2030 [2, 3].

The chronic inflammatory reaction of vessels in response to common cardiovascular risk factors and endothelial injuries represents the starting point in atherosclerotic development [4], able to lead to plaque formation. In fact, the most inflamed, vulnerable plaques are responsible for atherothrombotic events, such as acute myocardial infarction, stroke, and lower limb ischemia [5].

In the last years great efforts have been made in searching for drugs and/or molecules able to favourably limit the inflammatory atherosclerotic process. Carotenoids are currently considered beneficial substances. Among 700 carotenoids synthesized by plants, algae, and photosynthetic bacteria, about 50 are employed in the human diet, and 12 can be measured in blood and human tissues [6]. As free radicals scavenger and low-density lipoprotein cholesterol (LDL-C) resistance to oxidation inductors, several studies investigated the role of dietary carotenoids supplementation on cardiovascular risk reduction, others did not find any positive effects or even prooxidant actions. This paper aimed at defining the role of carotenoids supplementation on cardiovascular risk profile by reviewing literature data, paying attention to those carotenoids more present in our diet (β-carotene, α-carotene, β-cryptoxanthin, lycopene, lutein, zeaxanthin, and astaxanthin).

1. Introduction

Cardiovascular disease related to atherosclerosis represents the largest cause of morbidity and mortality in developed countries [1]. Despite the reduction of ischemic heart disease rates in the past three decades, recent estimates confirmed its pivotal role in determining the overall mortality until 2030 [2, 3].

The chronic inflammatory reaction of vessels in response to common cardiovascular risk factors and endothelial injuries represents the starting point in atherosclerotic development [4], able to lead to plaque formation. In fact, the most inflamed, vulnerable plaques are responsible for atherothrombotic events, such as acute myocardial infarction, stroke, and lower limb ischemia [5].

In the last years great efforts have been made in searching for drugs and/or molecules able to favourably limit the inflammatory atherosclerotic process. Carotenoids are currently considered beneficial substances. Among 700 carotenoids synthesized by plants, algae, and photosynthetic bacteria, about 50 are employed in the human diet, and 12 can be measured in blood and human tissues [6]. As free radicals scavenger and low-density lipoprotein cholesterol (LDL-C) resistance to oxidation inductors, several studies investigated the role of dietary carotenoids supplementation on cardiovascular disease (CVD) [6–9]. Nevertheless, results were contradictory at some extent.

We reviewed the role of some carotenoids (β-carotene, α-carotene, β-cryptoxanthin, lycopene, lutein, zeaxanthin, and astaxanthin) more commonly present in foods as well as the most widely studied.

2. Inflammation and CVD

The importance of oxidative stress and inflammation in atherosclerotic plaques development and CVD progression
is well known [10–12]. LDL-C oxidation represents the first step of initiation and progression of the atherosclerosis, in the setting of a global inflammatory process including oxidative stress, endothelial dysfunction, and vascular remodelling [13, 14].

On the basis of close interrelationship between oxidative stress, inflammation, and atherosclerosis, several studies have been performed to investigate the benefits of nutrients and food components with known antioxidant effects on cardiovascular health [15].

The antioxidant properties of vitamins C, E, and A seemed to be effective against different conditions able to promote CVD, that is, high blood pressure, impaired glucose and lipid profile, smoke abuse, with a positive influence on every step of atherosclerotic progression (endothelial dysfunction, LDL-C oxidation, monocyte, and smooth muscle cell activity) [16–18]. Nevertheless, even more important seems to be the role of carotenoids.

3. Carotenoids and Cardiovascular Health

The increased intake of fruit and vegetables is associated with lower mortality from all causes and with protective effects against CVD [19–21].

Great importance is attributed to the lifestyle improvement: abolition of tobacco use, increase in physical activity and the assumption of a healthy diet, based on high consumption of monounsaturated fats, fruit (rich in vitamins), vegetable fibres, olive oil, and cereals [22–24].

Many lines of evidence support the cardioprotective role of carotenoids in humans (see also Table 1).

It has been demonstrated that higher serum levels of carotenoids were associated with decreased risk of elevated serum NT-pro BNP levels, suggesting a role in preventing cardiac overload; moreover, high plasma levels of 𝛽-carotene and lutein were associated with lower risk of acute myocardial infarction [25, 26].

Several researchers have analyzed the influence of carotenoids on early stages of atherosclerosis. Low plasma lycopene levels were associated with subclinical atherosclerosis evaluated as an increase of intima-media thickness of the common carotid artery (CCA-IMT) in middle-aged men, while in healthy subjects an independent inverse relationship between serum levels of lycopene and brachial-ankle pulse wave velocity was found, considered as a marker of arterial stiffness [27, 28]. A recent 7-year follow-up study shows that high plasma levels of carotenoids protect against early vascular alterations assessed by CCA-IMT: changes in IMT was inversely associated with concentrations of lycopene, 𝛼-carotene, and 𝛽-carotene [29].

Patients with coronary artery disease showed to have lower plasma levels of lutein, zeaxanthin, 𝛽-cryptoxanthin, 𝛼-carotene, 𝛽-carotene, and lycopene compared to healthy subjects; moreover, the reduced levels of lutein, zeaxanthin, and 𝛽-cryptoxanthin were associated with smoking, high body mass index, and low high-density lipoprotein cholesterol (HDL-C) [30].

Recent lines of evidence showed even beneficial effect of carotenoids in primary prevention by delaying the onset of well-established cardiovascular risk factors.

In a healthy elderly population, it has been shown that plasma carotenoid levels have an independent relationship to the onset of dysglycemia: the risk of impaired fasting glucose or type 2 diabetes at 9-year was significantly lower in subjects with higher plasma carotenoid levels as compared to patients with lower carotenoid levels, even after adjusting for confounding factors [31]. The anti-hypertensive effect of carotenoids is supported by a follow-up study in which the concentrations of sum of four serum carotenoids (𝛼-carotene, 𝛽-carotene, lutein/zeaxanthin, and cryptoxanthin) were inversely correlated with incident hypertension after 20 years [32].

Many studies have focused on molecular mechanisms underlying the atheroprotective effects of carotenoids in cardiovascular disease.

At this purpose, an inverse correlation between plasma levels of provitamin A carotenoids and matrix metalloproteinase-9 was found, suggesting that the benefits of these nutrients can be attributable to reduced degradation of the extracellular matrix in the arterial wall [33]. Lycopene assumed with the diet by using tomato juice, spaghetti sauce, and tomato oleoresin reduced serum lipid peroxidation and LDL-C oxidation although it was not able to decrease serum values of total cholesterol, LDL-C, or HDL-C. [34]. The supplementation with astaxanthin has shown positive effects by improving the LDL-C, ApoB, and oxidative stress biomarkers in a placebo-controlled study performed on overweight and obese adults [35]; also, in nonobese subjects the astaxanthin consumption lowers triglycerides and increases HDL-C and serum adiponectin [36]. Another study showed an inverse relationship between serum levels of carotenoids and marker of oxidative stress (circulating extracellular superoxide dismutase), inflammation (leukocyte count, C-reactive protein), and endothelial dysfunction (soluble P-selectin, soluble intercellular adhesion molecule-1 (sICAM1)) [37].

In smoker subjects the Haematococcus astaxanthin supplementation had reduced levels of oxidative stress biomarkers, and for some of these the decreasing was dose-dependent, showing the role of this nutrient in preventing oxidative damage induced by cigarette smoking [38]. Regarding the antioxidant power and the free radical scavenger activity, the astaxanthin can be considered more effective than 𝛽-carotene and lycopene [39].

These encouraging results have been confirmed in early atherosclerosis patients, in which serum carotenoids were inversely associated with inflammatory cytokines [40].

Hence, these molecules by improving lipid profile, suppressing lipid peroxidation, and reinforcing the activity of the antioxidant system are able to contrast vascular wall inflammation, stabilize membrane properties in opposition to pathophysiologic steps of atherosclerosis, and reduce the risk of CVD.

Vitamins E and C seem to reduce total and coronary artery diseases mortality [41, 42].

Nevertheless, two studies showed that the increased intake of vitamins E and C and 𝛽-carotene compared to
| Source                  | Year | Design                                                                 | Aims                                                                 | Results                                                                 |
|------------------------|------|------------------------------------------------------------------------|----------------------------------------------------------------------|-------------------------------------------------------------------------|
| Ito et al. [43]        | 2006 | New analysis of a cohort from the Lipid Research Clinics Coronary Primary Prevention Trial and follow-up study. | To examine the relationship between total serum carotenoid levels and the risk of subsequent coronary heart disease events. | Higher serum carotenoid levels were associated with a decreased risk of incidence of coronary heart disease. This finding was stronger among men who never smoked. |
| Shaish et al. [44]     | 2006 | Prospective and cross sectional-study.                                | To assess the relationship between plasma levels of carotenoids (α- and β-carotene, lutein, lycopene, zeaxanthin, and beta-cryptoxanthin), vitamins A and E, and atherosclerosis in the carotid and femoral arteries. | α- and β-carotene plasma levels were inversely associated with the prevalence of atherosclerosis in the carotid and femoral arteries ($P = 0.004$) and with the 5-year incidence of atherosclerotic lesions in the carotid arteries ($P = 0.04$). |
| Street et al. [45]     | 1994 | Observational study (study cohort consisted of 26 593 male smokers, aged 50 to 69 years, without a history of stroke, during a 6.1-year followup). | Association between dietary antioxidants and subtypes of stroke       | The dietary intake of β-carotene was inversely associated with the risk for cerebral infarction, lutein plus zeaxanthin with risk for subarachnoid hemorrhage, and lycopene with risks of cerebral infarction and intracerebral hemorrhage. |
| Street et al. [46]     | 1994 | Observational epidemiologic study.                                    | To examine the association between lycopene and acute coronary events and stroke in middle-aged men previously free of these events. | Low serum level of lycopene is associated with an increased risk of atherosclerotic vascular events. |
| Karppi et al. [47]     | 2013 | Meta-analysis (seven randomised trials of vitamin E treatment and eight of β-carotene one). | To assess the effect of α-tocopherol (vitamin E), β-carotene, or both on long-term cardiovascular mortality and morbidity. | Vitamin E did not provide benefit in mortality or significantly decrease risk of cardiovascular death or cerebrovascular accident (p<ns). β-carotene led to a small but significant increase in all-cause mortality ($P = 0.003$) and cardiovascular death ($P = 0.003$). |
| Shaish et al. [48]     | 2006 | Prospective study (73 286 female nurses followed for 12 years for the development of incident CAD). | Dietary intakes of specific carotenoids and risk of CAD in women.    | Higher intakes of foods rich in α-carotene or β-carotene are associated with a reduction in risk of CAD. |
| Schürks et al. [49]    | 2010 | Prospective, nested case control analysis.                            | Plasma lycopene and risk of CVD in middle-aged and elderly women.    | Higher plasma lycopene concentrations are associated with a lower risk of CVD in women. |
| Sesso et al. [50]      | 2004 | Observational epidemiologic study (3061 subjects aged 39 to 80 years). | Serum carotenoids and CVD mortality risk.                            | High serum levels of total carotene, comprising α- and β-carotenes and lycopene, may reduce the risk for CVD mortality. |
| Howard et al. [51]     | 1996 | A case-control study (760 patients with nonfatal AMI and 682 controls patients) | The intake of selected carotenoids and retinol and risk of AMI.      | The risk of AMI decreased with increasing intake of α-carotene ($OR = 0.71, 95\% CI 0.51–0.98$, for the highest versus the lowest quartile of intake), β-carotene ($OR = 0.71, 95\% CI 0.50–1.01$), and β-cryptoxanthin ($OR = 0.64, 95\% CI 0.46–0.88$). No associations emerged for total carotenoids, lycopene, lutein plus zeaxanthin, and retinol. |
placebo did not reduce the incidence of all-cause and cardiovascular mortality [58, 59].

Meta-analyses did not support the benefits of antioxidant vitamins dietary supplementation in prevention of heart diseases and stroke, even proving a sort of harmful effect on health due to β-carotene and vitamin E supplementation [49, 52–54, 60, 61].

Despite these negative results, prospective studies demonstrated that plasma levels of these nutrients were related to CVD risk: after a 4.8 years follow-up, women with higher levels of circulating carotenoids showed a reduction in CVD risk: in a Japanese follow-up study (11.9-years), high carotenoids serum levels were associated with lower CVD mortality and, in a placebo-controlled trial with 13-year-followup period, higher serum carotenoids levels were related to a decreased risk of incident coronary heart disease [43, 50, 62].

Similarly, lower blood concentrations of carotenoids were associated with an increased incidence of atherosclerotic vascular events, that is, acute coronary syndrome and stroke [46, 63]. Nevertheless, many studies have yielded conflicting results, by emphasizing the uncertainty regarding the protective role of antioxidant action of carotenoids on coronary heart disease or, even, by underlining that increased intake of β-carotene and vitamin A does not allow cardioprotective effects but conversely correlates with increased risk of cardiovascular events [64–66].

Further studies are needed in order to fully understand the real impact of carotenoids on CVD risk control and to establish their potential therapeutic role.

3.1. β-Carotene. The β-carotene is an efficient quencher of singlet oxygen and comprises several isomers (i.e., all-trans and 9-cis β-carotene) able to inhibit the oxidative modification of LDL-C, with all-trans isomer more effective than 9-cis β-carotene [67, 68].

Navab et al. demonstrated that β-carotene did not reduce monocyte migration, while, pretreatment of smooth muscle cell and endothelial cell cocultures with β-carotene, before the addition of LDL-C, inhibited monocytes adhesion and their transmigration [69]. The same findings were obtained with LDL-C isolated from subjects with high intake of β-carotene [70].

In an experimental research, human endothelial cells were exposed to physiological concentration of β-carotene and to prooxidant conditions TNF-α induced. Results showed that antioxidant activity of β-carotene and lycopene opposed inflammatory oxidative stress and increased vascular nitric oxide bioavailability allowing protective effects against CVD [71].
Studies on animals suggest that all-trans \( \beta \)-carotene can inhibit atherosclerosis, independently from LDL-C resistance to oxidation [72]. LDL-C-receptor-knockout (LDL-R \( \sim \)) mice showed that 9-cis \( \beta \)-carotene reduces plasma cholesterol concentrations and area of atherosclerotic lesions [73].

The benefits of \( \beta \)-carotene may be due to its antioxidant activity and its skill in increasing HDL-C levels, as found in humans and transgenic mice studies [44].

Observational epidemiologic studies demonstrated the role of \( \beta \)-carotene in preventing CVD: its antioxidant activity showed to contrast the development of atherosclerotic lesions, while plasma levels of \( \alpha \)- and \( \beta \)-carotene seemed to be inversely associated with risk of carotid and femoral artery atherosclerosis [74].

Street et al. demonstrated a significantly inverse correlation between risk for subsequent myocardial infarction and lower levels of \( \beta \)-carotene [45].

In a clinical trial enrolling 26,593 male smokers followed up for 6.1 years, there was an inverse correlation between dietary intake of \( \beta \)-carotene and the occurrence of stroke [55].

A Finnish research pointed out that low serum \( \beta \)-carotene concentrations were associated with increased CVD mortality risk: men in the lowest quartile of \( \beta \)-carotene levels had a 2-fold increased risk of CVD mortality compared with those in the highest quartile, as well as sudden cardiac death and heart failure [56, 57]. In particular, men in the lowest quartile had almost 3-fold increased risk of heart failure as compared with the highest quartile group [47]. Thus, low concentrations of serum \( \beta \)-carotene were associated with increased mortality risk from heart disease, confirming the cardioprotective effects of carotenoids.

Nevertheless, other results did not support the beneficial role of \( \beta \)-carotene intake [52, 75].

In a randomized placebo-controlled trial, 22,071 apparently healthy males were asked to take \( \beta \)-carotene or placebo for 12 years; during the follow-up period, \( \beta \)-carotene supplementation did not influence cancer, CVD, or death incidence [76]. A 4-year combination of \( \beta \)-carotene and vitamin A showed no beneficial effects on death from lung cancer, CVD, and any cause in smokers and workers exposed to asbestos [77]. These conflicting results may be due to differences in trials performances: first, the human trials were performed by administering a synthetic all-trans \( \beta \)-carotene. The dose of \( \beta \)-carotene was higher than those in fruits and vegetables: the activity of carotenoids can be shifted from antioxidant to prooxidant according to their concentration, partial pressures of oxygen, or interactions with other coantioxidants (i.e., vitamins E and C) (see Figure 1) [48, 78–81]. Furthermore, as the dietary \( \beta \)-carotene is formed by several isomers like 9-cis and all-trans, it maybe that the 9-cis \( \beta \)-carotene provides more 9-cis retinoic acid than all-trans \( \beta \)-carotene with a subsequent more powerful result on the lipid profile [82].

3.2. \( \alpha \)-Carotene. \( \alpha \)-carotene plasma levels are inversely associated with risk of carotid and femoral artery atherosclerosis [74]. In particular, the higher intake of \( \alpha \)- and \( \beta \)-carotene-rich foods is associated with the lower incidence of CVD (nonfatal and fatal myocardial infarction) [83].

In a 13.9 years follow-up study involving 15,318 adults, serum concentrations of these carotenoids were inversely associated with risk of death from CVD, cancer, and death from all causes. Thus, intake of fruit and vegetables may lower mortality risk [84]. Small sample size studies confirmed these results [43, 51].

3.3. \( \beta \)-Cryptoxanthin. Plasma levels of \( \beta \)-cryptoxanthin influence CVD incidence. Buijsse et al. found that higher \( \beta \)-cryptoxanthin levels exerted a cardioprotective role: lower plasma levels were found in subjects coming from area with a high CVD incidence [85]. Iribarren et al. underlined that subjects with increased CCA-IMT had lower levels of \( \beta \)-cryptoxanthin, lutein, and zeaxanthin than controls [86]. In a prospective study performed on 638 subjects, with a follow-up period of 7.2 years, \( \beta \)-cryptoxanthin serum levels showed to be inversely associated with all-cause mortality [87].

This protective effect on risk of acute myocardial infarction was confirmed by Tavani et al. [88].

Nevertheless, some investigations did not support the protective role of \( \beta \)-cryptoxanthin.

In a prospective study, baseline blood samples from 28,345 females followed for 4.8 years were collected in order to evaluate the incidence of cardiovascular events (myocardial infarction, stroke, angina pectoris, cases of revascularization, and CVD death): 483 women who developed cardiovascular events were compared with events-free women. No significant correlation was found between higher plasma \( \beta \)-cryptoxanthin levels and CVD risk [62].

3.4. Lycopene. Lycopene mainly derives from tomatoes intake. Lower plasma levels of lycopene were associated with increased risk of atherosclerotic lesions, assessed by increased CCA-IMT, by the presence of calcified plaques in the abdominal aorta, and with an increased risk of acute coronary events or stroke [89–91]. In Sesso et al.’s work [50] higher plasma lycopene concentrations were associated with a lower risk of CVD in women.

Furthermore, in a case-control study performed in patients suffering from heart failure (NYHA class II-III), the left ventricular ejection fraction was significantly and positively correlated with plasma lycopene levels: NYHA class II patients showed significantly higher levels of lycopene than class III patients [92].

Nevertheless, some evidences showed no beneficial effects of lycopene on CVD risk reduction. In a prospective study (12 years followup) enrolling 73,286 females, Osganian et al. did not observe a significant association between high intake of lycopene and risk of CVD (nonfatal and fatal myocardial infarction), whereas higher intake of \( \alpha \)- and \( \beta \)-carotene-rich foods was associated with lower incidence of CVD [83]. Literature studies showed no significant association between serum lycopene concentration and CVD risk reduction in older men [93]; similarly, dietary intake of lycopene (tomato-based products) was not strongly associated with the risk of CVD in a prospective study on 39,876 women during a 7.2-year follow-up period [94].

In an epidemiologic Japanese follow-up study (11.9 years), high serum levels of lycopene were associated with low hazard
Carotenoids

Antioxidant activities

Prooxidant activities

(1) Scavengers of reactive oxygen species (singlet molecular oxygen and peroxyl radicals), at low partial pressures of oxygen, such as those found in most tissues under physiological conditions.
(2) Effective deactivators of electronically excited sensitizer molecules.
(3) Protection of cellular membranes and lipoproteins against oxidative damage (due to lipophilicity and specific property to scavenge peroxyl radicals).
(4) Cooperative effects with other antioxidants (i.e., vitamin C regenerates vitamin E in lipid systems, \( \beta \)-carotene tocopherol from the tocopheroxyl radical; vitamins E and C and \( \beta \)-carotene exhibit cooperative synergistic effects scavenging reactive nitrogen species).

(1) Increased production of bioactive free radical species.
(2) Alteration of the antioxidant defences.
(3) An increase in oxidative damage (oxidation of lipids, proteins, and DNA).

Conditions associated with prooxidant activities:
(a) high oxygen tension: \( \beta \)-carotene is readily autoxidized and exhibits prooxidant behaviour;
(b) carotenoid concentration: \( \beta \)-carotene at high concentrations shows prooxidant effects (probably for the formation of \( \beta \)-carotene peroxyl radicals and/or to a higher rate of autoxidation);
(c) low concentration of other antioxidants: in the presence of high concentrations of coantioxidants, carotenoids act as antioxidants, if coantioxidants are exhausted, they may evolve into prooxidant.

Figure 1: Antioxidant and prooxidant effects of carotenoids. The figure shows the antioxidant and the prooxidant effects of carotenoids, explaining the conditions that can make their effects harmful.

Among 123 patients suffering from myocardial infarction, serum levels of carotenoids, except lycopene, were inversely associated with myocardial infarction [96]. This association was strongest for \( \beta \)-carotene (\( P = 0.02 \)) and suggestive for lutein (\( P = 0.09 \)). An 8-year-followup study, performed on 43,738 men with no history of cardiovascular disease or diabetes, showed a significant inverse correlation between lutein intake and risk for ischemic stroke; in particular, the relative risk of stroke for the higher quintile of lutein intake compared with the bottom quintile was 0.72 [CI, 0.45 to 1.16] [97]. As regards congestive heart failure, NYHA class II patients showed significantly higher levels of lutein than class III patients; furthermore, a significant positive correlation was found between left ventricular ejection fraction and plasma lutein levels [92].

The carotenoids (i.e., lutein, lycopene, and \( \alpha \)- and \( \beta \)-carotene) plasma values on admission of acute ischemic stroke patients were lower than those of controls in Polidori’s research. Furthermore, only lutein levels were related to a worse prognosis: significantly lower levels of lutein were observed in patients with a poor outcome after ischemic stroke [98].
Nevertheless, several studies contrast previous results. In a case-control investigation, males without prior history of cardiovascular disease were followed for 13 years. 531 males developed myocardial infarction; thus their serum levels of 5 carotenoids (including lutein) were compared with those of controls: no evidence for a cardioprotective effect of higher baseline plasma levels of all carotenoids analyzed was detected [64].

In a follow-up study which enrolled 73,286 females, the higher intakes of \( \alpha \)- and \( \beta \)-carotene-rich foods were associated with lower incidence of CVD, although this association was not confirmed for lutein/zeaxanthin [83]. Blood samples coming from 28,345 middle-aged and elderly females followed up for 4.8 years for incidence of cardiovascular events did not support the benefits of higher plasma lutein/zeaxanthin levels in preventing CVD, as well as data from other studies [50, 74, 90]. Thus, further researches are needed in order to overcome the contrasting results of the literature.

3.6. Astaxanthin. The ketocarotenoid astaxanthin is the main carotenoid present in aquatic animals (salmon, trout, red seabream, shrimp, lobster, and fish eggs), contributing to the pinkish-red color of their flesh, and also in some birds (flamingoes and quails in particular).

Astaxanthin is biosynthesized by microalgae and phytoplankton, in fact the highest levels in nature were present in the Chlorophyte alga *Haematococcus pluvialis* [99].

Its molecular structure characterized by the presence of the hydroxyl and keto moieties on each ionone ring is responsible for its higher antioxidative activity; moreover, the oxofunction determines the powerful antioxidative properties without pro-oxidative contributions [100, 101]. This molecule demonstrated an important role in protection against oxidation and inflammation [102].

In fact, it showed to have the highest antioxidative activity toward peroxyl radicals among lutein, lycopene, \( \alpha \)-carotene, \( \beta \)-carotene, \( \alpha \)-tocopherol, and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid [103, 104]. Astaxanthin demonstrated to exert beneficial effects to heart both by reducing inflammation associated with atherosclerosis and by modifying blood levels of LDL-C and HDL-C, moreover it showed to significantly reduce macrophage infiltration and apoptosis in vascular lesions improving plaque stability by increasing adiponectin [105]. More recently Kishimoto et al. showed that astaxanthin could regulate the macrophage atherogenesis-related functions by suppressing the scavenger receptors upregulation, matrix metalloproteinases activation, and proinflammatory cytokines expression [106].

In addition, it was suggested that astaxanthin could have a potential therapeutic role in the management of myocardial injury, oxidized LDL-C, rethrombosis after thrombolysis, and other cardiac diseases such as atrial fibrillation [107].

The unfavourable findings may arise from the use of synthetic molecules slightly different from natural ones or by the competition between the plasma concentrations of carotenoids synthetically derived and of those normally taken with foods. The current data are promising, although further studies and a better standardization of methods are needed to obtain clearer results.

### References

[1] World Health Organization, *The World Health Report 2003: Shaping the Future*, World Health Organization, Geneva, Switzerland, 2003.

[2] C. D. Mathers and D. Loncar, “Projections of global mortality and burden of disease from 2002 to 2030,” *PLoS Medicine*, vol. 3, no. 11, Article ID e442, pp. 2011–2030, 2006.

[3] World Health Organization, *Preventing Chronic Diseases: 2005: A Vital Investment*, World Health Organization, Geneva, Switzerland, 2005.

[4] P. Libby, “Inflammation in atherosclerosis,” *Nature*, vol. 420, no. 6917, pp. 868–874, 2002.

[5] G. K. Hansson, “Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease,” *New England Journal of Medicine*, vol. 352, no. 16, pp. 1685–1626, 2005.

[6] S. Voutilainen, T. Nurmi, J. Mursu, and T. H. Rissanen, “Carotenoids and cardiovascular health,” *American Journal of Clinical Nutrition*, vol. 83, no. 6, pp. 1265–1271, 2006.

[7] P. Di Mascio, S. Kaiser, and H. Sies, “Lycopene as the most efficient biological carotenoid singlet oxygen quencher,” *Archives of Biochemistry and Biophysics*, vol. 274, no. 2, pp. 532–538, 1989.

[8] A. E. Agamey, G. M. Lowe, D. J. McGarvey et al., “Carotenoid radical chemistry and antioxidant/pro-oxidant properties,” *Archives of Biochemistry and Biophysics*, vol. 430, no. 1, pp. 37–48, 2004.

[9] G. Riccioni, L. Speranza, M. Pesce, S. Cusenza, N. D’Orazio, and M. J. Glade, “Novel phytotenutriont contributors to antioxidant protection against cardiovascular disease,” *Nutrition*, vol. 28, no. 6, pp. 605–610, 2012.

[10] T. E. Carew, “Role of biologically modified low-density lipoprotein in atherosclerosis,” *American Journal of Cardiology*, vol. 64, no. 13, pp. 18G–22G, 1989.

[11] J. A. Berliner, M. Navab, A. M. Fogelman et al., “Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics,” *Circulation*, vol. 91, no. 9, pp. 2488–2496, 1995.

[12] C. L. Allen and U. Bayraktutan, “Oxidative stress and its role in the pathogenesis of ischaemic stroke,” *International Journal of Stroke*, vol. 4, no. 6, pp. 461–470, 2009.

[13] G. Riccioni, N. D’Orazio, S. Franceschelli, and L. Speranza, “Marine carotenoids and cardiovascular risk markers,” *Marine Drugs*, vol. 9, no. 7, pp. 1166–1175, 2011.

[14] T. Gori and T. Münzel, “Oxidative stress and endothelial dysfunction: therapeutic implications,” *Annals of Medicine*, vol. 43, no. 4, pp. 259–272, 2011.

[15] A. Adameeva, Y. J. Xu, T. A. Duhamel, P. S. Tappia, L. Shan, and N. S. Dhall, “Anti-atherosclerotic molecules targeting oxidative stress and inflammation,” *Current Pharmaceutical Design*, vol. 15, no. 27, pp. 3094–3107, 2009.

[16] S. P. Juraschek, E. Guallar, J. L. Appel, and E. R. Miller III, “Effects of vitamin c supplementation on blood pressure: a meta-analysis of randomized controlled trials,” *American Journal of Clinical Nutrition*, vol. 95, no. 5, pp. 1079–1088, 2012.
[17] M. Fitó, M. Guixens, D. Corella et al., "Effect of a traditional Mediterranean diet on lipoprotein oxidation: a randomized controlled trial," *Archives of Internal Medicine*, vol. 167, no. 11, pp. 1195–1203, 2007.

[18] R. M. Salonen, K. Nyyssönen, J. Kaikkonen et al., "Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the antioxidant supplementation in atherosclerosis prevention (ASAP) study," *Circulation*, vol. 107, no. 7, pp. 947–953, 2003.

[19] H. Boeing, A. Bechthold, A. Bub et al., "Critical review: vegetables and fruit in the prevention of chronic diseases," *European Journal of Nutrition*, vol. 51, no. 6, pp. 637–663, 2012.

[20] A. J. Verlangieri, J. C. Kapeghian, S. El-Dean, and M. Bush, "Fruit and vegetable consumption and cardiovascular mortality," *Medical Hypotheses*, vol. 16, no. 1, pp. 7–15, 1985.

[21] F. J. He, C. A. Nowson, M. Lucas, and G. A. MacGregor, "Increased consumption of fruit and vegetables is related to a reduced risk of coronary heart disease: meta-analysis of cohort studies," *Journal of Human Hypertension*, vol. 21, no. 9, pp. 717–728, 2007.

[22] A. Bakhru and T. P. Erlinger, "Smoking cessation and cardiovascular disease risk factors: results from the third national health and nutrition examination survey," *PLoS Medicine*, vol. 2, no. 6, p. e160, 2005.

[23] J. I. Reddigan, C. I. Ardern, M. C. Riddell, and J. L. Kuk, "Relation of physical activity to cardiovascular disease mortality and the influence of cardiometabolic risk factors," *American Journal of Cardiology*, vol. 108, no. 10, pp. 1426–1431, 2011.

[24] M. A. Martínez-González, F. Guillén-Grima, J. De Irala et al., "The Mediterranean diet is associated with a reduction in premature mortality among middle-aged adults," *Journal of Nutrition*, vol. 142, no. 9, pp. 1672–1678, 2012.

[25] K. Suzuki, J. Ishii, F. Kitagawa et al., "Association of serum carotenoid levels with N-terminal pro-brain-type natriuretic peptide: a cross-sectional study in Japan," *Journal of Epidemiology & Community Health*, vol. 23, no. 3, pp. 163–168, 2013.

[26] W. P. Koh, J. M. Yuan, R. Wang et al., "Plasma carotenoids and risk of acute myocardial infarction in the Singapore Chinese Health Study," *Nutrition, Metabolism and Cardiovascular Diseases*, vol. 21, no. 9, pp. 685–690, 2011.

[27] T. Rissanen, S. Voutilainen, K. Nyyssönen, R. Salonen, and J. T. Salonen, "Low plasma lycopene concentration is associated with increased intima-media thickness of the carotid artery wall," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 20, no. 12, pp. 2677–2687, 2000.

[28] O. Y. Kim, H. Y. Yoe, H. J. Kim et al., "Independent inverse relationship between serum lycopene concentration and arterial stiffness," *Atherosclerosis*, vol. 208, no. 2, pp. 581–586, 2010.

[29] J. Karp, S. Kurz, K. Ronkainen, J. Kauhanen, and J. A. Laukkanen, "Serum carotenoids reduce progression of early atherosclerosis in the carotid artery wall among Eastern Finnish men," *PLoS ONE*, vol. 8, no. 5, Article ID e64107, 2013.

[30] C. Lidebjer, P. Leanderson, J. Ernerudh, and L. Jonasson, "Low plasma levels of oxygenated carotenoids in patients with coronary artery disease," *Nutrition, Metabolism and Cardiovascular Diseases*, vol. 17, no. 6, pp. 448–456, 2007.

[31] T. N. Akbaraly, A. Fonthone, A. Favier, and C. Berr, "Plasma carotenoids and onset of dysglycemia in an elderly population: results of the epidemiology of vascular ageing study," *Diabetes Care*, vol. 31, no. 7, pp. 1355–1359, 2008.

[32] A. Hozawa, D. R. Jacobs, M. W. Steffes, M. D. Gross, L. M. Steffen, and D. Lee, "Circulating carotenoid concentrations and incident hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) study," *Journal of Hypertension*, vol. 27, no. 2, pp. 237–242, 2009.

[33] M. Ryden, P. Garvin, M. Kristensen, P. Leanderson, J. Ernerudh, and L. Jonasson, "Provitamin A carotenoids are independently associated with matrix metalloproteinase-9 in plasma samples from a general population," *Journal of Internal Medicine*, vol. 272, no. 4, pp. 371–384, 2012.

[34] S. Agarwal and A. V. Rao, "Tomato lycopene and low density lipoprotein oxidation: a human dietary intervention study," *Lipids*, vol. 33, no. 10, pp. 981–984, 1998.

[35] H. D. Choi, Y. K. Youn, and W. G. Shin, "Positive effects of astaxanthin on lipid profiles and oxidative stress in overweight subjects," *Plant Foods for Human Nutrition*, vol. 66, no. 4, pp. 363–369, 2011.

[36] H. Yoshida, H. Yanai, K. Ito et al., "Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia," *Atherosclerosis*, vol. 209, no. 2, pp. 520–523, 2010.

[37] A. Hozawa, D. R. Jacobs Jr., M. W. Steffes, L. M. Steffen, and D. Lee, "Relationships of circulating carotenoid concentrations with several markers of inflammation, oxidative stress, and endothelial dysfunction: the Coronary Artery Risk Development in Young Adults (CARDIA)/Young Adult Longitudinal Trends in Antioxidants (YALTA) study," *Clinical Chemistry*, vol. 53, no. 3, pp. 447–455, 2007.

[38] J. H. Kim, M. J. Chang, H. D. Choi et al., "Protective effects of haematococcus astaxanthin on oxidative stress in healthy smokers," *Journal of Medicinal Food*, vol. 14, no. 11, pp. 1469–1475, 2011.

[39] S. Beutner, B. Bloedorn, S. Frixel et al., "Quantitative assessment of antioxidant properties of natural colorants and phytochemicals: carotenoids, flavonoids, phenols and indigoids. The role of β-carotene in antioxidant functions," *Journal of the Science of Food and Agriculture*, vol. 81, no. 6, pp. 559–568, 2001.

[40] X. R. Xu, Z. Y. Zou, Y. M. Huang, X. Xiao, L. Ma, and X. M. Lin, "Serum carotenoids in relation to risk factors for development of atherosclerosis," *Clinical Biochemistry*, vol. 45, no. 16–17, pp. 1357–1361, 2012.

[41] K. G. Losonczy, T. B. Harris, and R. J. Havlík, "Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the established populations for epidemiologic studies of the elderly," *American Journal of Clinical Nutrition*, vol. 64, no. 2, pp. 190–196, 1996.

[42] N. R. Sahyoun, P. F. Jacques, and R. M. Russell, "Carotenoids, vitamins C and E, and mortality in an elderly population," *American Journal of Epidemiology*, vol. 144, no. 5, pp. 501–511, 1996.

[43] Y. Ito, M. Kurata, K. Suzuki, N. Hamajima, H. Hishida, and K. Aoki, "Cardiovascular disease mortality and serum carotenoid levels: a Japanese population-based follow-up study," *Journal of Epidemiology*, vol. 16, no. 4, pp. 154–160, 2006.

[44] A. Shaish, A. Harari, L. Hananashvili et al., "9-cis β-carotene-rich powder of the alga Dunaliella bardawil increases plasma HDL-cholesterol in fibrate-treated patients," *Atherosclerosis*, vol. 189, no. 1, pp. 215–221, 2006.

[45] D. A. Street, G. W. Comstock, R. M. Salkeld, W. Schüep, and M. J. Kläg, "Serum antioxidants and myocardial infarction: are low levels of carotenoids and α-tocopherol risk factors for myocardial infarction?" *Circulation*, vol. 90, no. 3, pp. 1154–1161, 1994.
D. A. Street, G. W. Comstock, R. M. Salkeld, W. Schüp, and M. J. Klag, "Serum antioxidants and myocardial infarction: are low levels of carotenoids and α-tocopherol risk factors for myocardial infarction?" Circulation, vol. 90, no. 3, pp. 1154–1161, 1994.

J. Karppi, S. Kurl, T. H. Ma"akikallio, K. Ronkainen, and J. A. Laukkanen, "Serum β-carotene concentrations and the risk of congestive heart failure in men: a population-based study," International Journal of Cardiology, vol. 168, no. 3, pp. 1841–1846, 2013.

A. Shaish, A. Harari, L. Hananshivili et al., "9-cis β-carotene-rich powder of the alga Dunaliella bardawil increases plasma HDL-cholesterol in fibrate-treated patients," Atherosclerosis, vol. 189, no. 1, pp. 215–221, 2006.

M. Schürks, R. J. Glynn, P. M. Rist, C. Tzourio, and T. Kurth, "Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials," British Medical Journal, vol. 341, Article ID C5702, 2010.

H. D. Sesso, J. E. Buring, E. P. Norkus, and J. M. Gaziano, "Plasma lycopene, other carotenoids, and retinol and the risk of cardiovascular disease in women," American Journal of Clinical Nutrition, vol. 79, no. 1, pp. 47–53, 2004.

A. N. Howard, N. R. Williams, C. R. Palmer et al., "Do hydroxy-carotenoids prevent coronary heart disease? A comparison between Belfast and Toulouse," International Journal for Vitamin and Nutrition Research, vol. 66, no. 2, pp. 113–118, 1996.

G. Bjelakovic, D. Nikolova, L. L. Gluud, R. G. Simonetti, and S. K. Myung, W. Ju, B. Cho et al., "Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials," British Medical Journal, vol. 346, p. f10, 2013.

Q. Bin, X. Hu, Y. Cao, and F. Gao, "The role of vitamin E (tocopherol) supplementation in the prevention of stroke: a meta-analysis of 13 randomised controlled trials," Thrombosis and Haemostasis, vol. 105, no. 4, pp. 579–585, 2011.

T. Hirvonen, J. Virtamo, P. Korhonen, D. Albanes, and P. Pietinen, "Intake of flavonoids, carotenoids, Vitamins C and E, and risk of stroke in male smokers," Stroke, vol. 31, no. 10, pp. 2301–2306, 2000.

J. Karppi, J. A. Laukkanen, T. H. Mäikikallio, K. Ronkainen, and S. Kurl, "Low β-carotene concentrations increase the risk of cardiovascular disease mortality among Finnish men with risk factors," Nutrition, Metabolism and Cardiovascular Diseases, vol. 22, no. 10, pp. 921–928, 2012.

J. Karppi, J. A. Laukkanen, T. H. Mäikikallio, K. Ronkainen, and S. Kurl, "Serum β-carotene and the risk of sudden cardiac death in men: a population-based follow-up study," Atherosclerosis, vol. 226, no. 1, pp. 172–177, 2013.

Heart Protection Study Collaborative Group, "MRC/BHF heart protection study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial," The Lancet, vol. 360, no. 9236, pp. 23–33, 2002.

G. J. Hankey, "Vitamin supplementation and stroke prevention," Stroke, vol. 43, no. 10, pp. 2814–2818, 2012.

Y. Ye, J. Li, and Z. Yuan, "Effect of antioxidant vitamin supplementation on cardiovascular outcomes: a meta-analysis of randomized controlled trials," PLoS ONE, vol. 8, no. 2, Article ID e56803, 2013.

D. P. Vivekananthan, M. S. Penn, S. K. Sapp, A. Hsu, and E. J. Topol, "Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials," The Lancet, vol. 361, no. 9374, pp. 2017–2023, 2003.

D. L. Morris, S. B. Kritchevsky, and C. E. Davis, "Serum carotenoids and coronary heart disease: the lipid research clinics coronary primary prevention trial and follow-up study," Journal of the American Medical Association, vol. 272, no. 18, pp. 1439–1441, 1994.

T. H. Rissanen, S. Voutilainen, K. Nyysönen et al., "Low serum lycopene concentration is associated with an excess incidence of acute coronary events and stroke: the Kuopio Ischaemic Heart Disease Risk Factor Study," British Journal of Nutrition, vol. 85, no. 6, pp. 749–754, 2001.

A. E. Hak, M. J. Stamper, H. Campos et al., "Plasma carotenoids and tocopherols and risk of myocardial infarction in a low-risk population of US male physicians," Circulation, vol. 108, no. 7, pp. 802–807, 2003.

R. W. Evans, B. Jessica Shaten, B. W. Day, and L. H. Kuller, "Prospective association between lipid soluble antioxidants and coronary heart disease in men. The multiple risk factor intervention trial," American Journal of Epidemiology, vol. 147, no. 2, pp. 180–186, 1998.

G. S. Omenn, G. E. Goodman, M. D. Thornquist et al., "Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease," New England Journal of Medicine, vol. 334, no. 18, pp. 1510–1515, 1996.

I. Jialal, E. P. Norkus, L. Cristol, and S. M. Grundy, "β-Carotene inhibits the oxidative modification of low-density lipoprotein," Biochimica et Biophysica Acta, vol. 1086, no. 1, pp. 134–138, 1991.

A. Lavy, A. Ben Amotz, and M. Aviram, "Preferential inhibition of LDL oxidation by the all-trans isomer of β-carotene in comparison with 9-cis β-carotene," European Journal of Clinical Chemistry and Clinical Biochemistry, vol. 31, no. 2, pp. 83–90, 1993.

M. Navab, S. S. Imes, S. Y. Hama et al., "Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein," Journal of Clinical Investigation, vol. 88, no. 6, pp. 2039–2046, 1991.

P. D. Reaven, E. Ferguson, M. Navab, and F. L. Powell, "Susceptibility of human LDL to oxidative modification: effects of variations in β-carotene concentration and oxygen tension," Arteriosclerosis and Thrombosis, vol. 14, no. 7, pp. 1162–1169, 1994.

P. Di Tomo, R. Canali, D. Ciavardelli et al., "β-Carotene and lycopene affect endothelial response to TNF-α reducing nitro-oxidative stress and interaction with monocytes," Molecular Nutrition and Food Research, vol. 56, no. 2, pp. 217–227, 2012.

A. Shaish, A. Daugherty, F. O’Sullivan, G. Schonfeld, and J. W. Heinecke, "Beta-carotene inhibits atherosclerosis in hypercholesterolemic rabbits," Journal of Clinical Investigation, vol. 96, no. 4, pp. 2075–2082, 1995.

A. Harari, D. Harats, D. Marko et al., "A 9-cis β-carotene-enriched diet inhibits atherogenesis and fatty liver formation in LDL receptor knockout mice," Journal of Nutrition, vol. 138, no. 10, pp. 1923–1930, 2008.

A. D’Odorico, D. Martines, S. Kiechl et al., "High plasma levels of α- and β-carotene are associated with a lower risk of atherosclerosisResults from the Bruneck study," Atherosclerosis, vol. 153, no. 1, pp. 231–239, 2000.
[75] D. P. Vivekananthan, M. S. Penn, S. K. Sapp, A. Hsu, and E. J. Topol, "Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials," The Lancet, vol. 361, no. 9374, pp. 2017–2023, 2003.

[76] C. H. Hennekens, J. E. Buring, J. E. Manson et al., "Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease," New England Journal of Medicine, vol. 334, no. 18, pp. 1145–1149, 1996.

[77] G. S. Omenn, G. E. Goodman, M. D. Thornequist et al., "Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease," New England Journal of Medicine, vol. 334, no. 18, pp. 1150–1155, 1996.

[78] P. Palozza, "Prooxidant actions of carotenoids in biologic systems," Nutrition Reviews, vol. 56, no. 9, pp. 257–265, 1998.

[79] A. J. Young and G. M. Lowe, "Antioxidant and prooxidant properties of carotenoids," Archives of Biochemistry and Biophysics, vol. 385, no. 1, pp. 20–27, 2001.

[80] E. Niki, N. Noguchi, H. Tsuchihashi, and N. Gotoh, "Interaction among vitamin C, vitamin E, and β-carotene," American Journal of Clinical Nutrition, vol. 62, supplement 6, pp. 1322S–1326S, 1995.

[81] T. G. Truscott, "β-Carotene and disease: a suggested prooxidant and anti-oxidant mechanism and speculations concerning its role in cigarette smoking," Journal of Photochemistry and Photobiology B, vol. 35, no. 3, pp. 233–235, 1996.

[82] F. Böhm, R. Edge, D. J. McGarvey, and T. G. Truscott, "β-Carotene with vitamins E and C offers synergistic cell protection against NO(x)," FEBS Letters, vol. 436, no. 3, pp. 387–389, 1998.

[83] S. K. Osganian, M. J. Stampfer, E. Rimm, D. Spiegelman, J. E. Manson, and W. C. Willett, " Dietary carotenoids and risk of coronary artery disease in women," American Journal of Clinical Nutrition, vol. 77, no. 6, pp. 1390–1399, 2003.

[84] C. Li, E. S. Ford, G. Zhao, L. S. Balluz, W. H. Giles, and S. Liu, "Serum α-carotene concentrations and risk of death among US adults: the third national health and nutrition examination survey follow-up study," Archives of Internal Medicine, vol. 171, no. 6, pp. 507–515, 2011.

[85] B. Buïjssse, E. J. M. Feskens, L. Kwaape, F. J. Kok, and D. Kromhout, "Both α- and β-carotene, but not tocopherols and vitamin C, are inversely related to 15-year cardiovascular mortality in Dutch elderly men," Journal of Nutrition, vol. 138, no. 2, pp. 344–350, 2008.

[86] C. Iribarren, A. R. Folsom, D. R. Jacobs Jr., M. D. Gross, J. D. Belcher, and J. H. Eckfeldt, "Association of serum vitamin levels, LDL susceptibility to oxidation, and autoantibodies against MDA-LDL with carotid atherosclerosis: a case- control study," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 6, pp. 1171–1177, 1997.

[87] F. G. De Waart, E. G. Schouten, A. F. H. Stalenhoef, and F. J. Kok, "Serum carotenoids, α-tocopherol and mortality risk in a prospective study among Dutch elderly," International Journal of Epidemiology, vol. 30, no. 1, pp. 136–143, 2001.

[88] A. Tavani, S. Gallus, E. Negri, M. Parpinel, and C. La Vecchia, "Dietary intake of carotenoids and retinol and the risk of acute myocardial infarction in Italy," Free Radical Research, vol. 40, no. 6, pp. 659–664, 2006.

[89] T. H. Rissanen, S. Voutilainen, K. Nyyssönen, R. Salonen, G. A. Kaplan, and J. T. Salonen, "Serum lycopene concentrations and carotid atherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factor Study," American Journal of Clinical Nutrition, vol. 77, no. 1, pp. 133–138, 2003.

[90] K. Klipstein-Grobusch, L. J. Launer, J. M. Geleijnse, H. Boeing, A. Hofman, and J. C. M. Witteman, "Serum carotenoids and atherosclerosis: the Rotterdam Study," Atherosclerosis, vol. 148, no. 1, pp. 49–56, 2000.

[91] T. H. Rissanen, S. Voutilainen, K. Nyyssönen et al., "Low serum lycopene concentration is associated with an excess incidence of acute coronary events and stroke: the Kuopio Ischaemic Heart Disease Risk Factor Study," British Journal of Nutrition, vol. 85, no. 6, pp. 749–754, 2001.

[92] M. C. Polidori, K. Savino, G. Albanu et al., "Plasma lipophilic antioxidants and malondialdehyde in congestive heart failure patients: relationship to disease severity," Free Radical Biology and Medicine, vol. 32, no. 2, pp. 148–152, 2002.

[93] H. D. Sesso, J. E. Buring, E. P. Norkus, and J. M. Gaziano, "Plasma lycopene, other carotenoids, and retinol and the risk of cardiovascular disease in men," American Journal of Clinical Nutrition, vol. 81, no. 5, pp. 990–997, 2005.

[94] H. D. Sesso, S. Liu, J. M. Gaziano, and J. E. Buring, "Dietary lycopene, tomato-based food products and cardiovascular disease in women," Journal of Nutrition, vol. 133, no. 7, pp. 2336–2341, 2003.

[95] J. H. Dwyer, M. Navah, K. M. Dwyer et al., "Oxigenated carotenoid lutein and progression of early atherosclerosis: the Los Angeles atherosclerosis study," Circulation, vol. 103, no. 24, pp. 2922–2927, 2001.

[96] D. A. Street, G. W. Comstock, R. M. Salkeld, W. Schüep, and M. J. Klag, "Serum antioxidants and myocardial infarction: are low levels of carotenoids and α-tocopherol risk factors for myocardial infarction?" Circulation, vol. 90, no. 3, pp. 1154–1161, 1994.

[97] A. Ascherio, E. B. Rimm, M. A. Hernán et al., "Relation of consumption of vitamin E, vitamin C, and carotenoids to risk for stroke among men in the United States," Annals of Internal Medicine, vol. 130, no. 12, pp. 963–970, 1999.

[98] M. C. Polidori, A. Cherubini, W. Stahl, U. Senin, H. Sies, and P. Mecocci, "Plasma carotenoid and malondialdehyde levels in ischemic stroke patients: relationship to early outcome," Free Radical Research, vol. 36, no. 3, pp. 265–268, 2002.

[99] J. P. Yuan, J. Peng, K. Yin, and J. H. Wang, "Potential health-promoting effects of astaxanthin: a high-value carotenoid mostly from microalgae," Molecular Nutrition and Food Research, vol. 55, no. 1, pp. 150–165, 2011.

[100] H. Martin, C. Jäger, C. Ruck, M. Schmidt, R. Walsh, and J. Paust, "Anti- and prooxidant properties of carotenoids," Advanced Synthesis and Catalysis, vol. 341, no. 3, pp. 302–308, 1999.

[101] Y. Kishimoto, M. Tani, H. Uto-Kondo et al., "Astaxanthin suppresses scavenger receptor expression and matrix metalloproteinase activity in macrophages," European Journal of Nutrition, vol. 49, no. 2, pp. 119–126, 2010.

[102] M. Guerin, M. E. Huntley, and M. Olaiola, "Haematococcus astaxanthin: applications for human health and nutrition," Trends in Biotechnology, vol. 21, no. 5, pp. 210–216, 2003.

[103] M. Kurashige, E. Okimasu, M. Inoue, and K. Utsumi, "Inhibition of oxidative injury of biological membranes by astaxanthin," Physiological Chemistry and Physics and Medical NMR, vol. 22, no. 1, pp. 27–38, 1990.

[104] Y. M. A. Naguib, "Antioxidant activities of astaxanthin and related carotenoids," Journal of Agricultural and Food Chemistry, vol. 48, no. 4, pp. 1150–1154, 2000.

[105] W. Li, A. Hellsten, L. S. Jacobsson, H. M. Blomqvist, A. G. Olsson, and X. Yuan, "Alpha-tocopherol and astaxanthin..."
decrease macrophage infiltration, apoptosis and vulnerability in atheroma of hyperlipidaemic rabbits,” *Journal of Molecular and Cellular Cardiology*, vol. 37, no. 5, pp. 969–978, 2004.

[106] Y. Kishimoto, M. Tani, H. Uto-Kondo et al., “Astaxanthin suppresses scavenger receptor expression and matrix metalloproteinase activity in macrophages,” *European Journal of Nutrition*, vol. 49, no. 2, pp. 119–126, 2010.

[107] F. J. Pashkow, D. G. Watumull, and C. L. Campbell, “Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease,” *American Journal of Cardiology*, vol. 101, no. 10, pp. 58D–68D, 2008.